AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC

AstraZeneca (AZN) announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer.The regulatory body has approved Tagrisso for the treatment of unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) in adult patients whose disease has not progressed following treatment with chemoradiotherapy.Following the latest nod, Tagrisso is now indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations, as determined b ...